secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2026-06-05T20:19:10+00:00
Accession:  0001434647-26-000041
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra shareholders elect directors, ratify auditor; board declassification fails
--------------------------------------------------------------------------------

- Douglas W. Calder elected as Class II director with 25.8M for, 8.0M withheld (12.6M broker non-votes).
- Corey Watton elected as Class II director with 29.9M for, 3.8M withheld (12.6M broker non-votes).
- Ratification of Ernst & Young as auditor for FY 2026 approved: 45.9M for, 234.8K against, 144.6K abstain.
- Proposal to declassify board failed; received 32.6M for vs. 1.1M against, needed >66-2/3% of outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/0001434647-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/zvra-20260604.htm
  HTML page:      https://secwatch.observer/filing/0001434647-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer